List of Excipients in Branded Drug INDOMETHACIN EXTENDED-RELEASE

« Back to Dashboard

Generic Drugs Containing INDOMETHACIN EXTENDED-RELEASE

Company	Ingredient	NDC	Excipient
H J Harkins Company inc	indomethacin extended-release	52959-082	ETHYLCELLULOSE
H J Harkins Company inc	indomethacin extended-release	52959-082	FERROSOFERRIC OXIDE
H J Harkins Company inc	indomethacin extended-release	52959-082	GELATIN
H J Harkins Company inc	indomethacin extended-release	52959-082	POTASSIUM HYDROXIDE
H J Harkins Company inc	indomethacin extended-release	52959-082	POVIDONES
H J Harkins Company inc	indomethacin extended-release	52959-082	PROPYLENE GLYCOL
H J Harkins Company inc	indomethacin extended-release	52959-082	SHELLAC

What are the Most Frequently-Used Excipients in INDOMETHACIN EXTENDED-RELEASE?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10
3	ETHYLCELLULOSE
1	ETHYLCELLULOSES
1	FD&C BLUE NO. 1
1	FD&C BLUE NO. 2
1	FD&C GREEN NO. 3
1	FD&C RED NO. 40

Indomethacin Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Indomethacin extended-release is an established, genericized oral dosage form with limited active-ingredient patent protection and a larger opportunity in formulation execution. Commercial value depends on reliable modified-release performance, low manufacturing cost, controlled gastrointestinal exposure, and a regulatory package that supports ANDA approval or a differentiated 505(b)(2) product.

What is the market status of indomethacin extended-release?

Indomethacin is a nonsteroidal anti-inflammatory drug approved for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute painful shoulder, and acute gouty arthritis. Extended-release products are intended for chronic treatment where once- or twice-daily dosing is commercially useful. Immediate-release indomethacin remains important for conditions requiring faster onset.[1]

The principal reference product is Indocin SR, historically marketed as a 75 mg extended-release capsule. Generic indomethacin extended-release capsules have been approved through abbreviated new drug applications.

Attribute	Indomethacin extended-release
Active ingredient	Indomethacin
Drug class	NSAID
Common extended-release strength	75 mg
Original reference product	Indocin SR
Dosage form	Modified-release oral capsule
Primary regulatory route for generics	ANDA under Section 505(j)
Biosimilar exposure	None; this is a small-molecule drug
Main commercial issues	Bioequivalence, dissolution control, GI tolerability, manufacturing cost
Main formulation risk	Dose dumping or excessive early release
Patent position	Core composition and original formulation protection are generally expired

The product is not a biologic and therefore has no biosimilar pathway. Competition comes from generic manufacturers, authorized-generic arrangements, and potentially differentiated modified-release products.

What excipients are used in indomethacin extended-release capsules?

The precise excipient profile varies by manufacturer and should be confirmed against the current FDA-approved product label and ANDA records. Reference and generic products commonly use conventional solid-dose excipients such as fillers, binders, lubricants, glidants, capsule-shell materials, and release-controlling components.[2]

Potential excipient functions include:

Excipient function	Candidate materials	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Controls fill weight and powder flow
Binder	Povidone, hydroxypropyl cellulose, pregelatinized starch	Improves granule strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Controls initial matrix breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports capsule filling and compression
Glidant	Colloidal silicon dioxide, talc	Improves flow and content uniformity
Release modifier	Hypromellose, ethylcellulose, methacrylate copolymers	Controls drug diffusion or erosion
Pellet coating	Ethylcellulose, hypromellose, polymer dispersions	Enables multiparticulate release control
Capsule shell	Gelatin or hydroxypropyl methylcellulose	Provides dosage-form enclosure
Opacifier or colorant	Titanium dioxide and approved colorants	Supports identification and branding

Indomethacin is a weak acid with low aqueous solubility under acidic conditions and greater solubility at higher pH. That profile makes pH-dependent release, particle size, wetting, and gastrointestinal transit important formulation variables.[3]

A product developer should not assume that an excipient used in an immediate-release indomethacin product will produce acceptable extended-release performance. The release mechanism must be designed around drug solubility, dose loading, particle-size distribution, and the desired plasma profile.

Which extended-release excipient platforms are most commercially attractive?

Hydrophilic matrix capsules

A hydrophilic matrix based on hypromellose is the lowest-complexity platform for a new generic or line extension. Indomethacin is dispersed in a polymeric matrix that hydrates after administration. Drug release occurs through a combination of diffusion, matrix swelling, and erosion.

Advantages include:

• Low formulation complexity.
• Broad availability of compendial excipient grades.
• Straightforward scale-up.
• Potential use of standard blending, granulation, and encapsulation equipment.
• Lower coating cost than multiparticulate systems.

The principal risks are variable release at different agitation rates, sensitivity to polymer viscosity, and inadequate control of early drug release. High drug loading can make it difficult to form a robust matrix without producing an overly large capsule.

Hydrophobic matrix systems

Ethylcellulose, waxes, glyceryl behenate, and related hydrophobic materials can reduce the rate of water penetration and drug diffusion. This approach can produce more sustained release but may create excessive batch-to-batch variability if particle size, mixing energy, or lubricant distribution changes.

Hydrophobic matrices may be commercially attractive where a manufacturer has existing lipid-matrix technology. They are less attractive when the company lacks experience controlling content uniformity and dissolution across scale.

Multiparticulate pellets

Pellet-filled capsules can combine an immediate-release fraction with sustained-release coated pellets. Different coating thicknesses can create a controlled release profile across the gastrointestinal tract.

This platform offers the strongest technical control but carries higher manufacturing cost. Critical variables include:

• Pellet size distribution.
• Drug-layer uniformity.
• Coating weight gain.
• Polymer permeability.
• Seal-coat integrity.
• Capsule fill uniformity.
• Mechanical stress during filling and shipping.

Multiparticulate products may reduce the risk of a single-unit dose dumping event because the dose is distributed across many pellets. That benefit can support a premium strategy, but it must be demonstrated through dissolution and, where necessary, in vivo studies.

Enteric or pH-responsive systems

Enteric protection can delay indomethacin release until the dosage form reaches a higher-pH intestinal environment. This may reduce direct gastric exposure, but it does not eliminate systemic NSAID-related gastrointestinal, renal, or cardiovascular risks.

A pH-responsive design creates several regulatory risks:

• Delayed or incomplete release in patients with variable intestinal pH.
• Sensitivity to food and gastric emptying.
• Need for multi-stage dissolution testing.
• Potential mismatch with the reference product’s absorption profile.
• Risk that the formulation will be treated as a clinically differentiated product rather than a straightforward generic.

Enteric protection is therefore more suitable for a 505(b)(2) strategy than for a low-cost ANDA unless the reference product itself has a comparable release mechanism.

How should an excipient strategy address indomethacin’s physicochemical risks?

The development target should be a reproducible plasma exposure profile, not simply a slow dissolution curve. Indomethacin has a relatively narrow separation between useful anti-inflammatory exposure and dose-limiting toxicity. The formulation should avoid a high early-release pulse while preserving adequate absorption.

Particle size and wetting

Reducing drug particle size can improve dissolution but may increase the risk of excessive early release. A controlled particle-size specification, rather than the smallest achievable size, is usually commercially preferable.

Wetting agents can improve dispersion, but surfactant levels must be controlled because they may alter release, interact with capsule shells, or create food-condition differences.

Polymer selection

Polymer viscosity grade, substitution type, particle size, and hydration behavior can materially change release. The formulation should establish a design space linking polymer concentration and grade to:

• Initial release.
• Midpoint release.
• Terminal release.
• Release sensitivity to agitation.
• Release in acidic and buffer stages.
• Stability after storage.

Lubrication control

Over-lubrication with magnesium stearate can slow wetting and alter release. It can also reduce granule strength and affect capsule-fill behavior. Lubricant blending time should be a controlled process parameter.

Capsule-shell compatibility

Gelatin and hydroxypropyl methylcellulose shells can have different moisture-transfer properties. Shell selection affects stability, brittleness, dissolution behavior, and compatibility with hygroscopic excipients. A low-moisture formulation may favor HPMC capsules where gelatin cross-linking or moisture migration presents a risk.

What FDA regulatory pathway applies to indomethacin extended-release?

A conventional generic product would normally use the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[4]

For an extended-release capsule, the development package generally includes:

1. Pharmaceutical equivalence in strength, dosage form, route, and active ingredient.
2. Comparative dissolution testing across multiple media and agitation conditions.
3. Stability data using the proposed commercial container-closure system.
4. In vivo pharmacokinetic bioequivalence, unless a waiver is applicable.
5. Manufacturing controls for modified-release performance.
6. Labeling consistent with the reference product.
7. Evaluation of food effects where required by the product-specific regulatory framework.

The FDA’s modified-release guidance emphasizes that dissolution testing should discriminate between formulations and detect changes that could affect clinical performance.[5]

A 505(b)(2) application may be appropriate where the sponsor changes the release mechanism, dosage regimen, food profile, or tolerability positioning. This pathway can support a differentiated product but typically requires more clinical and regulatory investment than an ANDA.

What patent and exclusivity barriers affect commercial entry?

Indomethacin’s original active-ingredient and foundational formulation patents are long expired. The principal commercial barriers are therefore regulatory execution, manufacturing capability, market access, and pricing rather than basic compound patent protection.

Protection type	Current commercial relevance
Original compound patent	Expired
Original Indocin SR formulation protection	Generally expired
FDA drug exclusivity	No meaningful new-drug exclusivity expected for an established genericized product
Orange Book listed patents	Must be checked against the current Orange Book and reference product record
Paragraph IV risk	Relevant only if a currently listed patent remains applicable
Formulation patents	Possible for later-developed release technologies, but not necessarily blocking for a conventional generic
Method-of-use patents	May affect particular indications if listed and enforceable, but do not automatically block all generic sales
Trade secrets	Can remain relevant for pellet coating, scale-up, and process controls

A Paragraph IV certification could create patent litigation if a relevant patent is listed against the reference product. For an older product, the more likely outcome is a certification strategy focused on no patent listed, patent expiration, or non-infringement. The Orange Book should be reviewed at the time of filing because listing status can change.[6]

No biosimilar litigation is relevant because indomethacin is a small molecule.

What formulation patents could protect a new indomethacin extended-release product?

A new entrant is more likely to obtain narrow formulation or process claims than broad composition claims. Potential claim categories include:

• Specific polymer ratios.
• Multiparticulate coating structures.
• Defined release profiles.
• Combination immediate-release and extended-release fractions.
• Particle-size distributions.
• pH-triggered coating systems.
• Low-dose-dumping formulations.
• Manufacturing processes that improve content uniformity.
• Capsule-shell and moisture-control systems.
• Stabilized formulations with defined impurity limits.

Patent strength depends on claim breadth, enablement, freedom-to-operate against existing polymer and coating patents, and whether the formulation produces a clinically meaningful benefit. A patent that covers only a narrow excipient ratio may have limited defensive value if competitors can design around the range.

The strongest commercial position would combine a formulation patent with process know-how and a measurable regulatory advantage, such as reduced food effect or a demonstrably improved pharmacokinetic profile.

What commercial opportunities exist for indomethacin extended-release?

Low-cost generic supply

The clearest opportunity is a cost-efficient 75 mg extended-release capsule. Success depends on:

• Reliable API supply.
• High capsule-fill throughput.
• Low coating or granulation cost.
• Robust dissolution across scale.
• Competitive wholesaler and payer contracts.
• Adequate manufacturing capacity to avoid shortages.

Because the product is mature, pricing pressure is likely. A manufacturer needs either a structural cost advantage or a dependable supply position.

Authorized generic or licensing deal

A branded or specialty manufacturer could license an existing ANDA, acquire a product family, or create an authorized generic arrangement. Licensing value would depend on:

• Approved strengths.
• Current annual units.
• Manufacturing site status.
• Product-specific regulatory history.
• Back orders or shortage history.
• Payer concentration.
• Gross-to-net economics.

The opportunity is more attractive as part of a broader NSAID portfolio than as a standalone asset.

Differentiated 505(b)(2) product

A new product could target:

• Reduced dosing frequency.
• Lower peak concentration.
• More consistent exposure.
• Reduced food sensitivity.
• Delayed gastric release.
• A combined immediate-release and extended-release profile.

A differentiated product would require evidence that the formulation solves a clinically relevant problem. A premium price is difficult to sustain if the only difference is a new excipient system without a demonstrated patient or prescriber benefit.

Specialty distribution

Indomethacin has established use in rheumatology and acute gout. A manufacturer could use specialty distribution, digital adherence programs, or disease-focused sales only if the formulation has a meaningful clinical or dosing advantage. A conventional generic is more likely to compete through retail, mail-order, and group purchasing channels.

How does indomethacin extended-release compare with competing NSAID products?

Product category	Commercial advantage	Formulation opportunity
Immediate-release indomethacin	Faster onset and broad generic availability	Low-cost oral solid dose
Extended-release indomethacin	Reduced dosing frequency	Controlled-release matrix or pellets
Naproxen extended-release	Established chronic-use market	Larger competitive base and broader payer familiarity
Diclofenac modified-release	Strong formulation segmentation	Higher competition and safety scrutiny
Celecoxib	COX-2 selectivity and chronic-use positioning	Different clinical and patent history
Ketoprofen extended-release	Similar modified-release rationale	Smaller market and lower commercial scale

Indomethacin has a strong efficacy reputation but a narrower tolerability profile than several competing NSAIDs. That limits the value of a purely incremental extended-release design.

What generic launch scenarios exist?

Scenario 1: Conventional ANDA launch

A sponsor uses a standard matrix or pellet technology, matches the reference product’s release profile, and competes on price. This is the most probable route and has the lowest development risk.

Scenario 2: Supply-constrained entry

A manufacturer enters during a shortage or after a competitor exits. The commercial opportunity can be attractive, but FDA supply expectations, quality systems, and rapid scale-up become critical.

Scenario 3: Formulation-differentiated 505(b)(2) launch

A sponsor claims improved dosing convenience or exposure control. This route has higher clinical costs and patent-development requirements but may support a higher price.

Scenario 4: Portfolio acquisition

A company acquires an approved generic or licenses it with other NSAID products. The value comes from manufacturing utilization, contracting leverage, and shared distribution rather than indomethacin alone.

How strong is the patent estate for indomethacin extended-release?

The foundational patent estate is weak as an entry barrier because the drug and original extended-release product are mature. A later entrant can still build a narrower estate around a new release architecture, but the patent must survive obviousness, written-description, and design-around challenges.

The strongest protection is likely to come from a combined package:

• A composition claim covering the release system.
• A process claim covering manufacture.
• A dissolution-profile limitation tied to pharmacokinetic performance.
• Trade-secret controls over coating, blending, and scale-up.
• Regulatory exclusivity where a 505(b)(2) product qualifies.

Key Takeaways

• Indomethacin extended-release is a mature, genericized small-molecule opportunity.
• The primary commercial product is a 75 mg modified-release capsule.
• Excipient selection should prioritize dose-dumping control, dissolution reproducibility, moisture stability, and low-cost manufacture.
• Hydrophilic matrices offer the lowest-complexity generic strategy.
• Multiparticulate pellets provide stronger release control but increase manufacturing cost.
• Enteric and pH-responsive technologies are more suitable for a differentiated 505(b)(2) product than for a basic ANDA.
• Compound and original formulation patent barriers are generally expired.
• Current Orange Book listings, ANDA status, and product-specific patents must be reviewed before filing or licensing.
• The most practical commercial opportunities are low-cost generic entry, supply-reliable portfolio expansion, authorized-generic arrangements, and selected formulation differentiation.
• Biosimilar risk does not apply.

FAQs

Is indomethacin extended-release still protected by a compound patent?

No. The original indomethacin compound protection expired long ago. Any relevant current protection would more likely involve a later formulation, manufacturing process, or method-of-use patent.

Can a generic manufacturer use the same excipients as Indocin SR?

A generic manufacturer can use the same excipients if they are suitable, permitted, and supported by the ANDA. Exact qualitative and quantitative sameness may not be required for every excipient, but the formulation must meet pharmaceutical equivalence, bioequivalence, safety, and performance requirements.

Is an enteric-coated indomethacin capsule automatically substitutable for extended-release indomethacin?

No. Enteric coating and extended release are distinct formulation characteristics. A product with a different release mechanism may require a separate regulatory strategy and may not qualify as therapeutically equivalent to the reference product.

What is the largest manufacturing risk for indomethacin extended-release?

The largest risk is failure to maintain the intended dissolution profile during scale-up and shelf life. Polymer grade, drug particle size, lubrication, coating uniformity, moisture, and capsule-shell behavior can all affect release.

Does extended-release indomethacin eliminate NSAID gastrointestinal risk?

No. Modified release can change the timing of exposure but does not eliminate systemic NSAID risks, including gastrointestinal, renal, cardiovascular, and hypersensitivity risks.[1]

References

1. U.S. Food and Drug Administration. (n.d.). Indomethacin prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Indocin SR prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
3. National Center for Biotechnology Information. (n.d.). Indomethacin compound summary. PubChem. https://pubchem.ncbi.nlm.nih.gov/
4. U.S. Food and Drug Administration. (2023). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
5. U.S. Food and Drug Administration. (1997). SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes. https://www.fda.gov/
6. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/_久久爱